Biologics, treatment-to-target, CVD prevention are likely factors
Source: Survival Improving at Rapid Clip for RA Patients | Medpage Today
Biologics, treatment-to-target, CVD prevention are likely factors
Source: Survival Improving at Rapid Clip for RA Patients | Medpage Today
Mortality rates among patients with rheumatoid arthritis (RA) have come down over the past decade or so but are still 40% to 50% higher among patients with RA than the general population, Canadian researchers report.
Osteoporosis: A Common Complication
of Rheumatoid Arthritis
When you think about who’s at risk for osteoporosis, a stereotypical portrait probably comes to mind: a thin Caucasian or Asian woman who’s over age 50. But if you have rheumatoid arthritis (RA), add yourself to that picture.
In fact, according to a 2010 study in Arthritis Research & Therapy, people with RA are 1.5 times more likely to experience an osteoporosis-related fracture than those who don’t have RA. The study, which looked at the medical claims records of about 47,000 U.S. residents with RA and 235,000 without it, found that women face the greatest odds, but men are at risk as well. What’s more, the increased risk of fracture is seen across all age groups, although the chances of experiencing a fracture heighten with age. The most likely location of a fracture? The hip, followed by the pelvis, thighbone and wrist.
What raises the risk? Although scientists are still trying to sort out why people with RA are more likely to develop osteoporosis than others, they do know some of the factors that heighten risk.
You are receiving this email as part of your free subscription to Johns Hopkins Health Alerts. Should you wish to unsubscribe, please follow the instructions below. Help us be sure this email Health Alert isn’t filtered as spam. Adding our return address to your address book may “whitelist” us with your filter, helping future Health Alerts get to your inbox.
Did a friend send this to you? Sign up to get your own alert here
Email this to a friend
Unsubscribe from all Johns Hopkins Health Alert mailings
Subscribe to additional health alerts
Update your profile
Need to contact us? Click here: http://www.johnshopkinshealthalerts.com/contact_us/
Johns Hopkins Health Alerts
750 Third Avenue
6th Floor
New York, NY 10017
Attn: Web Team
We value your privacy and will not give your email address to anyone. Click here to view our privacy policy.
This information is not intended to substitute for the advice of a physician. Click here for additional information.
Copyright © 2014 Remedy Health Media, 750 Third Avenue, 6th Floor New York, New York, 10017. All rights reserved.
Another email blast from Johns Hopkins that I’ve shamelessly copied and redistributed. At least I’ve copied the Copyright. I do not nor ever will claim authorship, ownership, or attempt to redistribute for personal profit or gain the contents of this particular post.
Too much expert litigation work with attorneys. Can you tell?
RA Patients Living a Decade Longer.
The average age at death for RA patients in a cohort that enrolled patients between 1986 and 1998 was 76.7 years (95% CI 75-78.1), while for a cohort that enrolled patients between 2002 and 2012, the average age of death was 86.7 (95% CI 84.1-89.5), according toSam Norton, PhD, of King’s College in London.
Patients with rheumatoid arthritis (RA) have an increased incidence of diastolic dysfunction, which may further raise their already high risk for congestive heart failure, a meta-analysis suggested.
Patients with RA have double the incidence of heart failure compared with the larger population, and this finding has prompted interest in determining the origins of heart failure in these patients.
The FDA has expanded the black box warning to the label of the rheumatoid arthritis drug leflunomide (Arava) to include possible fatal liver damage.
The agency received 49 adverse event reports — including instances of jaundice, coagulopathy, encephalopathy, and 14 fatalities — about the drug from August 2002 to May 2009. Of the patients reporting adverse events, 36 were hospitalized.

Medical News: High Mortality with Lung Disease in RA – in Rheumatology, Arthritis from MedPage Today
Patients with rheumatoid arthritis (RA) who develop interstitial lung disease face a very high mortality risk, a population-based study found.
The risk of death for RA patients who develop interstitial lung disease was nearly triple compared with patients without pulmonary involvement (HR 2.86, 95% CI 1.98 to 4.12), according to Tim Bongartz, MD, and colleagues from the Mayo Clinic in Rochester, Minn.
And median survival of RA patients after a diagnosis of interstitial lung disease was only 2.6 years, considerably lower than the expected survival of 9.9 years for RA patients of the same age and sex without lung disease (P<0.001), the researchers reported in the June issue of Arthritis & Rheumatism.

You must be logged in to post a comment.